Source: MarketScreener

Lee's Pharm: Lee's Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

(marketscreener.com) China Oncology Focus, a subsidiary of Lee's Pharm, has enrolled the first patient in the Socazolimab double-blinded Phase 3 study in combination with chemotherapy as a first-line treatment of extensive-stage small-cell lung cancer.Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by...https://www.marketscreener.com/quote/stock/SORRENTO-THERAPEUTICS-IN-14708339/news/Lee-s-Pharmaceutical-Announces-First-Patient-Dosed-With-its-Anti-PD-L1-Antibody-Socazolimab-License-35934268/?utm_medium=RSS&utm_content=20210723

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
1-25
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100



Lee's Pharm is a Private company. Lee's Pharm generates $1M in revenue per employee Lee's Pharm has 2 followers on Owler.